Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.62 0.88 −4.29%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was -28.7% in Q3 FY26, the lowest of these four quarters. ROE, at 0.0%, is far above it because equity is small against the capital the business uses.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE0.0%0.0%0.0%0.0%
ROIC0.0%0.0%0.0%−28.7%

Debt

Net debt is 11.58× a year’s EBITDA.

Net debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Net debt / EBITDA12.8×5.3×7.7×11.6×
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Current Ratio
21.57 13.63 8.11 17.03

+3 more quarters

Net Debt/EBITDA
11.58 7.72 5.34 12.77
Debt/Assets
0.02% 0.16% 0.36% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Operating CF/Net income
0.92 0.91 0.36 0.20
Capex/Depreciation
0.00 2.67 (18.00) —
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% —
Free Cash Flow per Share
(0.47) (2.29) (0.76) (0.33)
Cash per Share
6.70 16.59 11.74 23.22
Shareholders Equity per Share
9.55 (12.96) (11.42) (17.15)
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
9.55 (12.96) (11.42) (17.15)
Free Cash Flow
(24.37) (16.94) (5.22) (1.27)
Working Capital
342.90 114.39 71.07 84.04
Capital Expenditures
0.00 0.01 (0.04) —
Net Current Asset Value
342.73 (99.42) (79.20) (65.94)
Other line items
Quick Ratio
20.95 13.56 8.06 17.01
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.47) (2.29) (0.76) (0.33)
Capex per Share
0.00 0.00 (0.01) 0.00
Capex to Sales
0.00 0.00 0.00 —

Fold the line items

Columns are period end dates · fundamentals updated 12 Nov 2026